Inappropriate use of meta-analysis to estimate efficacy of probiotics [1]

American Journal of Gastroenterology

Volumn 102, Issue 1, 2007, Pages 201-

  Dendukuri, Nandini ^a,b   Brophy, James ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROBIOTIC AGENT;

BACTERIUM CULTURE; CLOSTRIDIUM DIFFICILE; CONFIDENCE INTERVAL; DIARRHEA; DRUG EFFICACY; FOLLOW UP; HUMAN; INFECTION PREVENTION; INFECTIOUS DIARRHEA; LETTER; META ANALYSIS; OUTCOME ASSESSMENT; POPULATION; PRIORITY JOURNAL; SAMPLE SIZE;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; META-ANALYSIS; PROBIOTICS;

EID: 33846042589     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.00916.x     Document Type: Letter

References (4)

1. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006;101:812-22.
2. Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: A double-blind, placebo-controlled trial. Scand J Infect Dis 2003;35:365-7.
3. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-8.
4. Dendukuri N, Costa V, McGregor M, et al. A systematic review of probiotics for prevention and treatment of Clostridium difficile- associated diarrhea. Can Med Assoc J 2005;173:167-70.